Leukemia, Myelomonocytic, Acute clinical trials

The registry lists 188 studies for Leukemia, Myelomonocytic, Acute across more than 10 countries. 3 are recruiting or about to start. 13 of them are mainly about Leukemia, Myelomonocytic, Acute (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-13.

Get an email when these change. Save the Leukemia, Myelomonocytic, Acute studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 136
Terminated: 24
Status unknown: 15
Active, not recruiting: 5
Withdrawn: 4
Recruiting: 3

Phase

Phase 2: 87
Phase 1: 62
Phase 3: 26
Early Phase 1: 2
Phase 4: 1

Where

United States: 143
Canada: 14
France: 11
Italy: 10
Belgium: 8
Netherlands: 8

Who runs them

National Cancer Institute (NCI) (51) · SWOG Cancer Research Network (11) · Fred Hutchinson Cancer Center (10) · Roswell Park Cancer Institute (8) · European Organisation for Research and Treatment of Cancer - EORTC (8) · Case Comprehensive Cancer Center (7) · Eastern Cooperative Oncology Group (6) · Alliance for Clinical Trials in Oncology (6)

What is being tested here

Drugs under test in Leukemia, Myelomonocytic, Acute studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Cytarabine	1	3	47
Idarubicin	1	1	14
Gemtuzumab	1	6	13
Fludarabine phosphate	1	0	9
Fludarabine	1	0	9
Filgrastim	1	2	7
Filgrastim-sndz	1	0	1
Treosulfan	1	1	1
Daunorubicin	0	2	14
Etoposide	0	2	13

Drug classes tested here Antimetabolites 1 open · Alkylating agents 1 open · Tyrosine kinase inhibitors (TKIs) 9 · Calcineurin inhibitors 7 · HDAC inhibitors 6

Coming up

2phase 3 studies under way

0studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

Who these studies take

Of the 3 Leukemia, Myelomonocytic, Acute studies recruiting now, 1 (33%) set no upper age limit and 2 (67%) stop at 75 or younger. 1 (33%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.

Recruiting studies that take each age, of 3
Age	Women	Men
10	1 (33%)	1 (33%)
18	3 (100%)	3 (100%)
30	2 (67%)	2 (67%)
40	2 (67%)	2 (67%)
50	2 (67%)	2 (67%)
65	2 (67%)	2 (67%)
75	1 (33%)	1 (33%)
85	1 (33%)	1 (33%)

Across all 188 studies, recruiting or not: 34% stop at 75 or younger and 22% at 65; 27% take children; 1% are for women only and 0% for men only; 0% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Leukemia, Myelomonocytic, Acute studies take

Of 16 phase 2 interventional studies under Leukemia, Myelomonocytic, Acute, half reached primary completion within 60 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 2	60 mo50–81 · 16 studies	—	—

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

Studies

Recruiting first, then most recently updated. Showing 50 of 188. Browse all 188 → or search them.